Dianthus Sees Best-In-Class Potential For Claseprubart In Crowded gMG Market
Phase III Initiation, Data In Other Indications Due In 2026
Dianthus will test 300mg claseprubart dosed every two and four weeks in its Phase III myasthenia gravis trial (Shutterstock) 
